2025-05-02 11:04:05
Latest Post
Godrej Agrovet Limited consolidated Q4FY25 net profit drops QoQ to Rs. 70.78 crores
L G Balakrishnan & Bros Ltd posts Rs. 84.03 crores consolidated profit in Q4FY25
Swastika Investmart Ltd Q4 FY2025 consolidated profit slumps to Rs. 27.17 lakhs
Vertex Securities Ltd consolidated Q4 FY25 loss at Rs. 53.99 lakhs
The Federal Bank Limited consolidated Q4FY25 PAT jumps to Rs. 1108.31 crores
Stock Report
Marksans Pharma Q3FY22 consolidated profit at Rs. 48.27 crores
Posted On : 2022-02-11 14:46:45( TIMEZONE : IST )
Marksans Pharma Limited has reported Consolidated financial results for the period ended December 31, 2021.
Financial Results (Q3 FY2022) - QoQ Comparison
The company has reported total income of Rs. 374.690 crores during the period ended December 31, 2021 as compared to Rs. 369.768 crores during the period ended September 30, 2021.
The company has posted net profit / (loss) of Rs. 48.272 crores for the period ended December 31, 2021 as against net profit / (loss) of Rs. 46.288 crores for the period ended September 30, 2021.
The company has reported EPS of Rs. 1.20 for the period ended December 31, 2021 as compared to Rs. 1.11 for the period ended September 30, 2021.
| Financials | Q3 FY2022 | Q2 FY2022 | % Change |
| Total Income | ₹ 374.690 crs | ₹369.768 crs |  1.33% |
| Net Profit | ₹48.272 crs | ₹46.288 crs | 4.29% |
| EPS | ₹1.20 | ₹1.11 | 8.11% |
Financial Results (Q3 FY2022) - YoY Comparison
The company has reported total income of Rs. 374.690 crores during the period ended December 31, 2021 as compared to Rs.355.195 crores during the period ended December 31, 2020.
The company has posted net profit / (loss) of Rs.48.272 crores for the period ended December 31, 2021 as against net profit / (loss) of Rs.58.940 crores for the period ended December 31, 2020.
The company has reported EPS of Rs.1.20 for the period ended December 31, 2021 as compared to Rs.1.42 for the period ended December 31, 2020.
| Financials | Q3 FY2022 | Q3 FY2021 | % Change |
| Total Income | ₹ 374.690 crs | ₹355.195 crs | 5.49% |
| Net Profit | ₹48.272 crs | ₹58.940 crs |  -18.10% |
| EPS | ₹1.20 | ₹1.42 | -15.49% |
Financial Results (9 Months Ended FY2022) - YoY Comparison
The company has reported total income of Rs.1099.304 crores during the 9 Months period ended December 31, 2021 as compared to Rs.1046.667 crores during the 9 Months period ended December 31, 2020.
The company has posted net profit / (loss) of Rs.157.162 crores for the 9 Months period ended December 31, 2021 as against net profit / (loss) of Rs.159.039 crores for the 9 Months period ended December 31, 2020.
The company has reported EPS of Rs.3.82 for the 9 Months period ended December 31, 2021 as compared to Rs.3.83 for the 9 Months period ended December 31, 2020.
| Financials | 9 Months Ended FY2022 | 9 Months Ended FY2021 | % Change |
| Total Income | ₹1099.304 crs | ₹1046.667 crs | 5.03% |
| Net Profit | ₹157.162 crs | ₹159.039 crs | -1.18% |
| EPS | ₹3.82 | ₹3.83 | -0.26% |
Shares of Marksans Pharma Limited was last trading in BSE at Rs. 56.45 as compared to the previous close of Rs. 56.55. The total number of shares traded during the day was 97354 in over 1194 trades.
The stock hit an intraday high of Rs. 57.00 and intraday low of 56.05. The net turnover during the day was Rs. 5489673.00.
